Multimer Detection System-Oligomerized Amyloid Beta (MDS-OAβ): A Plasma-Based Biomarker Differentiates Alzheimer's Disease from Other Etiologies of Dementia. (2nd May 2022)

• Record Type: Journal Article
• Authors: Dominguez, Jacqueline Cotoong; Yu, Jeryl Ritzi Tan; De Guzman, Ma Fe; Ampil, Encarnita; Guevarra, Anne Cristine; Joson, Ma. Lourdes; Reandelar, Macario; Martinez, Ma. Socorro; Ligsay, Antonio; Ocampo, Ferron; Kim, SangYun
• Other Names: Abate Giulia Academic Editor.
• Is Part Of: International journal of alzheimer's disease. Volume 2022(2022)
• Publication Date: 2022-05-02
• Subjects: Alzheimer's disease -- Periodicals; 616.831005
• DOI: 10.1155/2022/9960832
• Languages: English
• ISSNs: 2090-8024

Abstract

Abstract : With emerging amyloid therapies, documentation of the patient's amyloid status to confirm the etiology of a clinical diagnosis is warranted prior to instituting amyloid-based therapy. The Multimer Detection System-Oligomeric Amyloid- β (MDS-OA β ) is a noninvasive blood-based biomarker utilized to measure A β oligomerization tendency. We determined the difference in MDS-OA β ratio across the groups: (a) no cognitive impairment or subjective cognitive impairment (NCI/SCI), (b) Alzheimer's disease (AD), (c) non-AD, and (d) mixed Alzheimer's disease-Vascular dementia (AD-VaD). MDS-OA β level was not significantly different between AD and mixed AD-VaD, but both groups were significantly different from the NCI/SCI and from the non-AD group. An MDS-OA β level of >1 could potentially indicate clinical variants of AD or mixed pathology (AD-VaD).